tiprankstipranks
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
US Market
JSPR
Jasper Therapeutics
RESEARCH TOOLSreports
Want to see JSPR full AI Analyst Report?

Jasper Therapeutics (JSPR) Stock Forecast & Price Target

1,060 Followers
See the Price Targets and Ratings of:

JSPR Analyst Ratings

Hold
3Ratings
Hold
0 Buy
3 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Jasper
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JSPR Stock 12 Month Forecast

Average Price Target

$3.00
▲(194.12% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Jasper Therapeutics in the last 3 months. The average price target is $3.00 with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 194.12% change from the last price of $1.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.454,0.6498461538461539,0.8456923076923077,1.0415384615384615,1.2373846153846153,1.433230769230769,1.629076923076923,1.8249230769230769,2.020769230769231,2.2166153846153844,2.4124615384615384,2.6083076923076924,2.8041538461538464,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.454,0.6498461538461539,0.8456923076923077,1.0415384615384615,1.2373846153846153,1.433230769230769,1.629076923076923,1.8249230769230769,2.020769230769231,2.2166153846153844,2.4124615384615384,2.6083076923076924,2.8041538461538464,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.454,0.6498461538461539,0.8456923076923077,1.0415384615384615,1.2373846153846153,1.433230769230769,1.629076923076923,1.8249230769230769,2.020769230769231,2.2166153846153844,2.4124615384615384,2.6083076923076924,2.8041538461538464,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.534,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.454,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$3.00Average Price Target$3.00Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on JSPR
Matt Phipps
William Blair
William Blair
―
Hold
―
Reiterated
06/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Jasper Therapeutics (NASDAQ: JSPR) and Corbus Pharmaceuticals (NASDAQ: CRBP)
TD Cowen Analyst forecast on JSPR
Yaron Werber
TD Cowen
TD Cowen
―
Hold
―
Downgraded
05/15/26
Jasper Therapeutics downgraded to Hold from Buy at TD CowenJasper Therapeutics downgraded to Hold from Buy at TD Cowen
RBC Capital Analyst forecast on JSPR
Leonid Timashev
RBC Capital
RBC Capital
$4→$3
Hold
194.12%
Upside
Reiterated
05/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Jasper Therapeutics (NASDAQ: JSPR) and Corvus Pharmaceuticals (NASDAQ: CRVS)
UBS Analyst forecast on JSPR
David Dai
UBS
UBS
$1.5
Hold
47.06%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (NASDAQ: JSPR), Alto Neuroscience, Inc. (NYSE: ANRO) and Viridian Therapeutics (NASDAQ: VRDN)
Evercore ISI Analyst forecast on JSPR
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$12→$7
Buy
586.27%
Upside
Reiterated
04/01/26
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISIJasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
H.C. Wainwright Analyst forecast on JSPR
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$20
Buy
1860.78%
Upside
Assigned
03/30/26
Buy Rating on Jasper: Briquilimab’s Strong CSU Efficacy, Favorable Safety, and Competitive Profile Underpin Key Near‑Term Value Driver
Rodman & Renshaw Analyst forecast on JSPR
Michael King
Rodman & Renshaw
Rodman & Renshaw
$17
Buy
1566.67%
Upside
Initiated
01/13/26
Jasper Therapeutics initiated with a Buy at Rodman & RenshawJasper Therapeutics initiated with a Buy at Rodman & Renshaw
BTIG Analyst forecast on JSPR
Justin Zelin
BTIG
BTIG
$7
Buy
586.27%
Upside
Reiterated
12/02/25
Positive Outlook for Jasper Therapeutics: Buy Rating Reinforced by Briquilimab's Promising Data and Strategic Plans
Citizens JMP Analyst forecast on JSPR
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$12→$6
Buy
488.24%
Upside
Reiterated
09/22/25
Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMPJasper Therapeutics price target lowered to $6 from $12 at Citizens JMP
Cantor Fitzgerald Analyst forecast on JSPR
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
07/07/25
Jasper Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldJasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on JSPR
Matt Phipps
William Blair
William Blair
―
Hold
―
Reiterated
06/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Jasper Therapeutics (NASDAQ: JSPR) and Corbus Pharmaceuticals (NASDAQ: CRBP)
TD Cowen Analyst forecast on JSPR
Yaron Werber
TD Cowen
TD Cowen
―
Hold
―
Downgraded
05/15/26
Jasper Therapeutics downgraded to Hold from Buy at TD CowenJasper Therapeutics downgraded to Hold from Buy at TD Cowen
RBC Capital Analyst forecast on JSPR
Leonid Timashev
RBC Capital
RBC Capital
$4→$3
Hold
194.12%
Upside
Reiterated
05/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Jasper Therapeutics (NASDAQ: JSPR) and Corvus Pharmaceuticals (NASDAQ: CRVS)
UBS Analyst forecast on JSPR
David Dai
UBS
UBS
$1.5
Hold
47.06%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (NASDAQ: JSPR), Alto Neuroscience, Inc. (NYSE: ANRO) and Viridian Therapeutics (NASDAQ: VRDN)
Evercore ISI Analyst forecast on JSPR
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$12→$7
Buy
586.27%
Upside
Reiterated
04/01/26
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISIJasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
H.C. Wainwright Analyst forecast on JSPR
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$20
Buy
1860.78%
Upside
Assigned
03/30/26
Buy Rating on Jasper: Briquilimab’s Strong CSU Efficacy, Favorable Safety, and Competitive Profile Underpin Key Near‑Term Value Driver
Rodman & Renshaw Analyst forecast on JSPR
Michael King
Rodman & Renshaw
Rodman & Renshaw
$17
Buy
1566.67%
Upside
Initiated
01/13/26
Jasper Therapeutics initiated with a Buy at Rodman & RenshawJasper Therapeutics initiated with a Buy at Rodman & Renshaw
BTIG Analyst forecast on JSPR
Justin Zelin
BTIG
BTIG
$7
Buy
586.27%
Upside
Reiterated
12/02/25
Positive Outlook for Jasper Therapeutics: Buy Rating Reinforced by Briquilimab's Promising Data and Strategic Plans
Citizens JMP Analyst forecast on JSPR
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$12→$6
Buy
488.24%
Upside
Reiterated
09/22/25
Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMPJasper Therapeutics price target lowered to $6 from $12 at Citizens JMP
Cantor Fitzgerald Analyst forecast on JSPR
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
07/07/25
Jasper Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldJasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jasper Therapeutics

3 Months
Michael KingRodman & Renshaw
Success Rate
2/8 ratings generated profit
25%
Average Return
+19.20%
Copying Michael King's trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of +19.20% per trade.
1 Year
Michael KingRodman & Renshaw
Success Rate
5/8 ratings generated profit
63%
Average Return
+0.66%
Copying Michael King's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +0.66% per trade.
2 Years
Michael KingRodman & Renshaw
Success Rate
2/8 ratings generated profit
25%
Average Return
+7.11%
Copying Michael King's trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of +7.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JSPR Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
3
2
2
1
0
Buy
0
0
0
0
0
Hold
5
4
7
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
6
9
6
4
In the current month, JSPR has received 0 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. JSPR average Analyst price target in the past 3 months is 3.00.
Each month's total comprises the sum of three months' worth of ratings.

JSPR Financial Forecast

JSPR Earnings Forecast

Next quarter’s earnings estimate for JSPR is -$0.30 with a range of -$0.44 to -$0.09. The previous quarter’s EPS was -$0.04. JSPR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year JSPR has Performed in-line its overall industry.
Next quarter’s earnings estimate for JSPR is -$0.30 with a range of -$0.44 to -$0.09. The previous quarter’s EPS was -$0.04. JSPR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year JSPR has Performed in-line its overall industry.
No data currently available

JSPR Sales Forecast

Next quarter’s sales forecast for JSPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. JSPR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year JSPR has Performed in-line its overall industry.
Next quarter’s sales forecast for JSPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. JSPR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year JSPR has Performed in-line its overall industry.

JSPR Stock Forecast FAQ

What is JSPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Jasper Therapeutics’s 12-month average price target is 3.00.
    What is JSPR’s upside potential, based on the analysts’ average price target?
    Jasper Therapeutics has 194.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JSPR a Buy, Sell or Hold?
          Jasper Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Jasper Therapeutics’s price target?
            The average price target for Jasper Therapeutics is 3.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $3.00 ,the lowest forecast is $3.00. The average price target represents 194.12% Increase from the current price of $1.02.
              What do analysts say about Jasper Therapeutics?
              Jasper Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of JSPR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.